Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein

US9707287B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Stephen S. Whitehead · Montgomery Village, US
• Brian R. Murphy · Bethesda, US
• Kathryn A. Hanley · Las Cruces, US
• Joseph E. Blaney · Frederick, US
• Ching-Juh Lai · Bethesda, US

Key dates

• Filing date: Dec 4, 2013
• Grant date: Jul 18, 2017
• Expiry date: Jan 18, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention features novel attenuated dengue virus mutants and compositions thereof. The invention further features an attenuated dengue virus comprising a proline to leucine change at amino acid position 2343 of non-structural protein 4B (NS4B), wherein the numbering is based upon the prototypic isolate DEN4 Dominica 1981 and the attenuated mutant DEN virus has at least one of the following properties: improved replication in Vero cells or restricted replication in mosquito cells.